Summary: Michael Mithoefer, M.D., and Sara Gael, M.A., of MAPS respond to key questions about MAPS’ pioneering work in the psychedelic field in Psychiatry Advisor’s Expert Q&A. Read the feature article to learn more about the gradual decrease of stigma surrounding psychedelics in psychiatry and society as a whole, the differences between psychedelic-assisted therapy and traditional psychiatric treatment options, the goals and progress of MAPS’ MDMA Therapy Training Program, and more.
Originally appearing here.